查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470873

患者异质骨移植/PDX 模型市场：按类型、肿瘤类型、应用和最终用户 - 2024-2030 年全球预测

Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models), Application, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

患者来源的异质骨移植/PDX模型市场规模预计2023年为2.2226亿美元，2024年达到2.5351亿美元，2030年将成长至5.7499亿美元，预计复合年增长率为14.54%。

患者来源的异种移植模型（PDX）是一种前沿的癌症研究模型，将人类肿瘤组织和细胞直接移植到免疫力缺乏或人源化小鼠体内，以在体内生长和维持患者的肿瘤，成为一种药物开发工具。全球癌症发生率不断上升，增加了对有效治疗方法的需求，并增加了对研发活动的投资。然而，与获取患者组织样本相关的伦理和监管问题以及人类和小鼠之间的生理差异限制了患者来源的异种移植（PDX）模式的发展。此外，政府对癌症研究的资助增加以及分子​​表征技术的进步预计将在未来创造利润丰厚的机会。

主要市场统计
基准年[2023] 2.2226亿美元
预测年份 [2024] 25351万美元
预测年份 [2030] 57499万美元
复合年增长率（%） 14.54%

小鼠模型广泛用于肿瘤学中以开发新的疗法。

小鼠模型是使用最广泛的 PDX 模型，因为它们体积小、易于操作且在基因上与人类相似。这些模型对肿瘤生物学的理解和肿瘤学新治疗方法的发展做出了重大贡献。另一方面，大鼠模型由于其体积大以及在外科手术、影像诊断和采样方面的优势，已成为小鼠 PDX 模型的有价值的替代品。此外，大鼠在模拟某些人类癌症类型（例如神经胶质瘤和肉瘤）时表现出更多样化的免疫反应和更高的保真度。

肿瘤类型：专注于妇科肿瘤模型，研究妇科癌症。

胃肠道 (GI) 肿瘤模型对于研究影响消化器官系统（例如大肠直肠癌、胃癌和胰腺癌）至关重要。这些模型可用于研究肿瘤发展和转移的潜在机制以及评估潜在的治疗方法。妇科肿瘤模型对于妇科癌症（包括卵巢、子宫内膜癌和子宫颈癌）的研究至关重要。血液肿瘤模型用于研究血液癌症，如白血病、淋巴瘤和多发性骨髓瘤。呼吸道肿瘤模型对于研究肺癌的病理和治疗方法至关重要。泌尿系统肿瘤模型对于研究泌尿器官系统癌症（例如膀胱癌、肾臟癌和前列腺癌）非常重要，它可以让研究人员了解疾病的发展并确定个人化的治疗策略。

应用：在基础癌症研究中越来越多地采用患者来源的异种移植（PDX）模型

患者来源的异质骨移植（PDX）模型在基础癌症研究中非常有价值，因为它们忠实地模拟了肿瘤环境和患者异质性。生物标记分析对于识别预测和预后标记以指导个别患者的治疗决策至关重要。 PDX 模型透过捕捉肿瘤生长和治疗反应的分子变化来实现全面的生物标记开发。临床前药物开发在很大程度上依赖 PDX 模型来评估临床实验药物的安全性、有效性和药物动力学特性。 PDX模型概括了人类癌症的复杂性和多样性，因此是进入临床试验前评估抗癌药物的首选。

最终用户：提高学术和研究机构中患者来源的异质骨移植的适用性

学术和研究机构主要促进癌症生物学、药效测试和个人化医疗开发的研究。这些机构使用 PDX 模型来识别新的治疗标靶并了解肿瘤进展的机制。委外研发机构(CRO) 使用 PDX 模型进行药物发现和研发，为製药和生物技术公司提供临床前和临床测试服务。 CRO 将这些模型应用于药物开发的各个阶段，包括标靶辨识/验证、先导药物最适化、药物动力学/动态(PK/PD) 测试和毒性评估。製药和生物技术公司正在采用 PDX 模型来支持其药物发现管道并满足个人化癌症治疗的需求。

区域洞察

由于政府的支持措施以及促进该领域进步的各种研究机构的存在，美洲的 PDX 市场高度发展。此外，该地区的生物技术公司在为药物发现和个人化医疗方法提供 PDX 服务方面具有巨大价值。在欧盟 (EU)，欧盟资助的计划重点在于扩大成员国对 PDX 模型的使用。中东地区对 PDX 建模研究的兴趣与日俱增，各组织纷纷采取倡议，为临床前癌症模型开发开发专业知识和资源。在亚太地区，生物医学研究的投入带动了国内药厂PDX模型研究的激增。亚太地区的政府框架也支持促进 PDX 模型研究的倡议，为患者来源的异质骨移植/PDX 模型市场开发潜在平台。

FPNV定位矩阵

FPNV定位矩阵对于评估患者来源的异质骨移植/PDX模型市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对患者异质骨移植/PDX 模型市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.患者异质骨移植/PDX模型市场的市场规模和预测是多少？

2.在病患异质骨移植/PDX模型市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.人异质骨移植/PDX模型市场的技术趋势与法规结构是什么？

4.在病患异质骨移植/PDX模型市场中主要供应商的市场占有率是多少？

5. 进入病人源性异质骨移植/PDX模型市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 个人化医疗需求不断成长
      • 肿瘤学和临床前开发
      • 为申请人准备临床前计划和文件提供政府计划资助和服务
    • 抑制因素
      • 个性化PDX模型高成本
    • 机会
      • 对人性化 PDX 模型的需求不断增长
      • 药物研发的成长
    • 任务
      • 在癌症研究中道德使用动物的严格准则
  • 市场区隔分析
    • 类型：透过在肿瘤学中广泛使用小鼠模型来开发新治疗方法
    • 肿瘤类型：聚焦妇科肿瘤模型，研究妇科癌症
    • 应用：扩大病患来源的异种移植（PDX）模型在基础癌症研究中的采用
    • 最终使用者：扩大学术研究机构中病患来源的异种移植的范围
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章患者异质骨移植/PDX 模型市场：依类型

  • 小鼠模型
  • 大鼠模型

第 7 章按肿瘤类型分類的病人异质骨移植/PDX 模型市场

  • 胃肠道肿瘤模型
  • 妇科肿瘤模型
  • 血液肿瘤模型
  • 呼吸道肿瘤模型
  • 泌尿系统肿瘤模型

第八章患者异质骨移植/PDX 模型市场：依应用分类

  • 基础癌症研究
  • 生物标记分析
  • 临床前药物开发

第 9 章 病患异质骨移植/PDX 模型市场：依最终使用者分类

  • 学术/研究机构
  • 合约调查机构
  • 製药和生物技术公司

第十章 美洲病患异质骨移植/PDX模型市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太患者异质骨移植/PDX模型市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的病人异质骨移植/PDX模型市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Kiyatec 和 Xenostart 正式宣布达成合作协议，将使用 Kiyatec 的 3D 球体筛检平台 Kiya-Predict 提供相关的体外疗效资料并帮助降低药物开发成本。
    • Soteria 和 Certis 合作使用 AI 平台和小鼠异种移植物生成药物反应预测
    • Gem Pharmatech 与 Charles River Laboratories 签署独家协议，分销下一代 NCG 产品组合
  • 战略分析和建议

第14章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-FF1601152744

[197 Pages Report] The Patient-Derived Xenograft/PDX Model Market size was estimated at USD 222.26 million in 2023 and expected to reach USD 253.51 million in 2024, at a CAGR 14.54% to reach USD 574.99 million by 2030.

A Patient-Derived Xenograft (PDX) model is an advanced cancer research and drug development tool that directly transplants human tumor tissues or cells into immunodeficient or humanized mice, allowing for the growth and maintenance of the patient's tumor in a living organism. The increasing prevalence of cancer worldwide drives demand for effective therapies, leading to increased investment in research and development activities. However, ethical and regulatory concerns associated with acquiring patient tissue samples and discrepancies between human and mouse physiology restrain the growth of the patient-derived xenograft (PDX) mode. Furthermore, increasing government funding initiatives for cancer research and advancements in molecular characterization techniques are expected to create lucrative opportunities in the future.

KEY MARKET STATISTICS
Base Year [2023] USD 222.26 million
Estimated Year [2024] USD 253.51 million
Forecast Year [2030] USD 574.99 million
CAGR (%) 14.54%

Type: Extensive use of mouse models in oncology to develop novel therapeutics

Mice models are the most widely used PDX models due to their properties such as small size, ease of handling, and genetic similarity to humans. These models contribute significantly to understanding tumor biology and developing novel therapeutic approaches in oncology. On the other hand, rat models have emerged as a valuable alternative to mice PDX models due to their larger size, which benefits surgical procedures, imaging, and sampling. Additionally, rats exhibit more diverse immune responses and higher fidelity in modeling certain human cancer types, such as glioma and sarcoma.

Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers

Gastrointestinal (GI) tumor models are crucial to studying cancers that affect the digestive system, such as colorectal, gastric, and pancreatic cancer. These models aid in examining the underlying mechanisms of tumor development and metastasis and evaluating potential therapeutic options. Gynecological tumor models are essential for studying gynecological cancers, including ovarian, endometrial, and cervical cancer. Researchers employ hematological tumor models to study blood cancers, including leukemia, lymphoma, and multiple myeloma. Respiratory tumor models are vital for investigating lung cancer pathogenesis and treatment options. Urological tumor models, crucial for studying cancers of the urinary system such as bladder, kidney, and prostate cancer, aid researchers in comprehending disease development and identifying personalized treatment strategies.

Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research

Patient-derived xenograft (PDX) models are highly valuable in basic cancer research as they closely mimic the tumor environment and patient heterogeneity. Biomarker analysis is essential for identifying predictive or prognostic markers that guide treatment decisions for individual patients. PDX models enable comprehensive biomarker development by capturing molecular changes during tumor growth and therapy response. Preclinical drug development relies heavily on PDX models to assess investigational therapies' safety, efficacy, and pharmacokinetic properties. They are a preferred choice for evaluating anticancer agents before entering clinical trials, as PDX models replicate the complexity and diversity of human cancers.

End-User: Rising applicability of patient-derived xenografts in academic and research institutes

Academic and research institutions primarily facilitate the study of cancer biology, drug efficacy testing, and personalized medicine development. These institutions use PDX models to identify novel therapeutic targets and understand tumor progression mechanisms. Contract Research Organizations (CROs) offer preclinical and clinical trial services for pharmaceutical and biotechnology companies using PDX models for drug discovery and development. CROs apply these models in various stages of drug development, including target identification/validation, lead optimization, pharmacokinetics/pharmacodynamics (PK/PD) studies, and toxicity evaluation. Pharmaceutical and biotechnology companies employ PDX models to support their drug discovery pipelines and address the demand for personalized oncology treatments.

Regional Insights

The patient-derived xenograft/PDX model market in the Americas is highly evolving due to supportive government initiatives and the presence of various research institutes that contribute to advancements in this field. Moreover, biotechnology companies in the region are significant in providing PDX services for drug discovery and personalized medicine approaches. In the European Union, EU-funded projects focus on expanding access to PDX models across member countries. The Middle East is witnessing an increasing interest in PDX model research, with initiatives led by organizations and fostering expertise and resources for preclinical cancer model development. Asia-Pacific region's investment in biomedical research has resulted in a surge of PDX model studies by domestic pharmaceutical companies. The government frameworks in the Asia-Pacific region also support initiatives that promote PDX model research, developing a potential platform for the patient-derived xenograft/PDX model market.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Patient-Derived Xenograft/PDX Model Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Patient-Derived Xenograft/PDX Model Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., Bioduro-Sundia, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience, Envigo RMS, LLC, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera Biolabs, Hera BioLabs Inc., Inotiv, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Merck KGaA, Oncodesign Services, Pharmatest Services Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, Vertiv Group Corp., WuXi AppTec Co., Ltd., and XENTECH.

Market Segmentation & Coverage

This research report categorizes the Patient-Derived Xenograft/PDX Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Mice Models
    • Rat Models
  • Tumor Type
    • Gastrointestinal Tumor Models
    • Gynecological Tumor Models
    • Hematological Tumor Models
    • Respiratory Tumor Models
    • Urological Tumor Models
  • Application
    • Basic Cancer Research
    • Biomarker Analysis
    • Preclinical Drug Development
  • End-User
    • Academic & Research Institutions
    • Contract Research Organizations
    • Pharmaceutical & Biotechnology Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Patient-Derived Xenograft/PDX Model Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Patient-Derived Xenograft/PDX Model Market?

3. What are the technology trends and regulatory frameworks in the Patient-Derived Xenograft/PDX Model Market?

4. What is the market share of the leading vendors in the Patient-Derived Xenograft/PDX Model Market?

5. Which modes and strategic moves are suitable for entering the Patient-Derived Xenograft/PDX Model Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for personalized medicine
      • 5.1.1.2. Oncology and preclinical development
      • 5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of personalized PDX model
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising demand for humanized PDX Model
      • 5.1.3.2. Growth in pharma R&D
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Extensive use of mouse models in oncology to develop novel therapeutics
    • 5.2.2. Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
    • 5.2.3. Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
    • 5.2.4. End-User: Rising applicability of patient-derived xenografts in academic and research institutes
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Patient-Derived Xenograft/PDX Model Market, by Type

  • 6.1. Introduction
  • 6.2. Mice Models
  • 6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

  • 7.1. Introduction
  • 7.2. Gastrointestinal Tumor Models
  • 7.3. Gynecological Tumor Models
  • 7.4. Hematological Tumor Models
  • 7.5. Respiratory Tumor Models
  • 7.6. Urological Tumor Models

8. Patient-Derived Xenograft/PDX Model Market, by Application

  • 8.1. Introduction
  • 8.2. Basic Cancer Research
  • 8.3. Biomarker Analysis
  • 8.4. Preclinical Drug Development

9. Patient-Derived Xenograft/PDX Model Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutions
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Patient-Derived Xenograft/PDX Model Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec's 3D Spheroid Screening Platform, Kiya-Predict
    • 13.3.2. Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts
    • 13.3.3. GemPharmatech and Charles River Laboratories Sign Exclusive Agreement to Distribute Next Generation NCG Portfolio
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
  • FIGURE 2. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
  • FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024